Kanzaki Ryu, Kanou Takashi, Ose Naoko, Funaki Soichiro, Shintani Yasushi, Minami Masato, Kida Hiroshi, Ogawa Kazuhiko, Kumanogoh Atsushi, Okumura Meinoshin
Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Respiratory Center, Osaka University Hospital, Osaka, Japan.
Interact Cardiovasc Thorac Surg. 2019 Mar 1;28(3):360-367. doi: 10.1093/icvts/ivy276.
The results of preoperative chemotherapy or chemoradiotherapy followed by surgery for locally advanced thymoma were analysed.
Between 1997 and 2016, 29 patients with a thymoma underwent preoperative chemotherapy or chemoradiotherapy followed by surgery. These cases were retrospectively reviewed.
The study population included 9 men and 20 women, with a mean age of 48.8 years (range 31-68 years). The preoperative Masaoka stage was III in 12, IVa in 13 and IVb in 4 patients, whereas histological type was B3 in 11, B2 in 9 and others in 5 patients. The mean tumour size was 8.0 ± 2.5 cm (3.4-15.0 cm). The site of infiltration shown in preoperative radiological examinations was the aorta in 6 patients, the superior vena cava in 14 patients and the pulmonary artery trunk in 3 patients, with pleural dissemination detected in 14. Three patients underwent chemoradiotherapy. Chemotherapy regimens given were cisplatin + doxorubicin + vincristine + cyclophosphamide in 9 patients, carboplatin + paclitaxel in 6 patients, cisplatin + doxorubicin + methylprednisolone in 5 patients and others in 9 patients, with partial response obtained in 11 patients and stable disease noted in 18 patients. Complete resection was achieved in 24 (83%) cases. There were no perioperative mortalities, whereas 6 (21%) patients developed postoperative complications. The 5- and 10-year overall survival rates were 100% and 87%, respectively, and 5- and 10-year disease-free survival rates were 50% and 50%, respectively.
Preoperative chemotherapy or chemoradiotherapy followed by surgery for locally advanced thymoma can be performed with an acceptable degree of surgical risk. Such a strategy should be proactively considered, as it can lead to favourable long-term results.
分析术前化疗或放化疗后行手术治疗局部晚期胸腺瘤的结果。
1997年至2016年间,29例胸腺瘤患者接受了术前化疗或放化疗后行手术治疗。对这些病例进行回顾性分析。
研究人群包括9名男性和20名女性,平均年龄48.8岁(范围31 - 68岁)。术前Masaoka分期为Ⅲ期的有12例,Ⅳa期的有13例,Ⅳb期的有4例,而组织学类型为B3型的有11例,B2型的有9例,其他类型的有5例。肿瘤平均大小为8.0±2.5 cm(3.4 - 15.0 cm)。术前影像学检查显示的浸润部位,侵犯主动脉的有6例,侵犯上腔静脉的有14例,侵犯肺动脉主干的有3例,14例有胸膜播散。3例接受了放化疗。化疗方案为顺铂+阿霉素+长春新碱+环磷酰胺的有9例,卡铂+紫杉醇的有6例,顺铂+阿霉素+甲泼尼龙的有5例,其他方案的有9例,11例获得部分缓解,18例病情稳定。24例(83%)实现了完整切除。围手术期无死亡病例,6例(21%)患者出现术后并发症。5年和10年总生存率分别为100%和87%,5年和10年无病生存率分别为50%和50%。
局部晚期胸腺瘤术前化疗或放化疗后行手术治疗,手术风险程度可接受。应积极考虑这种策略,因为它可带来良好的长期结果。